Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 17, 2016, Pages 2253-2266

  Caccese, M ^a   Ferrara, R ^a   Pilotto, S ^a   Carbognin, L ^a   Grizzi, G ^a   Calio A ^b   Brunelli, M ^b   Cuppone, F ^c   Petraglia, S ^c   Scarpa, A ^b   Tortora, G ^a   Bria, E ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c ITALIAN MEDICINES AGENCY   (Italy)

Author keywords

ALK inhibitors; Crizotinib; Lung cancer; resistance

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; BRIGATINIB; CERITINIB; CRIZOTINIB; ENSARTINIB; ENTRECTINIB; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; LORLATINIB; PEMETREXED; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; 7-AMINO-12-FLUORO-2,10,16-TRIMETHYL-15-OXO-10,15,16,17-TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO(4,3-H)(2,5,11)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE; ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; MACROCYCLIC LACTAM; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

BRAIN METASTASIS; CANCER THERAPY; CLINICAL PRACTICE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; NON SMALL CELL LUNG CANCER; REVIEW; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; LUNG NEOPLASMS; PERSONALIZED MEDICINE;

ANTINEOPLASTIC AGENTS; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LACTAMS, MACROCYCLIC; LUNG NEOPLASMS; PIPERIDINES; PRECISION MEDICINE; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84996588123     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1242578     Document Type: Review

References (132)

1. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001 Apr 5;344(14):1038–1042.
2. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001 Apr 5;344(14):1031–1037.
3. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15;347(7):472–480.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783–792.
5. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724–734.
6. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30;364(26):2507–2516.
7. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma:a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358–365.
8. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380–2388.
9. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121–128.
10. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947–957.• First evidence of the TKI gefitinib in comparision with chemotherapy in the context of a clinically selected patient population of lung adenocarcinoma, with the highest chance of carrying a sensitizing mutation of the EGFR gene.
11. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239–246.• First prospective evidence of the efficacy of TKI erlotinib in comparision with chemotherapy in patients with EGFR-mutated lung adenocarcinoma.
12. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327–3334.
13. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6):an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213–222.
14. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802):a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735–742.
15. Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer:results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016 Apr 2;387(10026):1415–1426.
16. Noonan SA, Berry L, Lu X, et al. Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis. J Thorac Oncol. 2016 Aug;11(8):1293–1304.
17. Rosell R, Karachaliou N., Large-scale screening for somatic mutations in lung cancer. Lancet. 2016 Apr 2;387(10026):1354–1356.
18. Stoica GE, Kuo A, Aigner A, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem. 2001 May 18;276(20):16772–16779.
19. Stoica GE, Kuo A, Powers C, et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002 Sep 27;277(39):35990–35998.
20. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997 Jan 30;14(4):439–449.
21. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16;455(7215):975–978.
22. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010 Mar 1;16(5):1561–1571.
23. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994 Mar 4;263(5151):1281–1284.
24. Iyevleva AG, Raskin GA, Tiurin VI, et al. Novel ALK fusion partners in lung cancer. Cancer Letters. 2015 Jun 28;362(1):116–121.
25. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008 Jul 1;68(13):4971–4976.
26. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008 Oct 15;14(20):6618–6624.
27. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008 Jan;8(1):11–23.
28. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008 Jul 1;14(13):4275–4283.
29. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009 Sep;7(9):1466–1476.
30. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008 Oct 16;455(7215):971–974.
31. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008 Oct 16;455(7215):967–970.
32. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008 Oct 16;455(7215):930–935.
33. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007 Dec 14;131(6):1190–1203.
34. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007 Aug 2;448(7153):561–566.•• The first work identifying the EML4-ALK genetic alteration in NSCLC.
35. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement:a retrospective analysis. Lancet Oncol. 2011 Oct;12(11):1004–1012.
36. Scagliotti G, Stahel RA, Rosell R, et al. ALK translocation and crizotinib in non-small cell lung cancer:an evolving paradigm in oncology drug development. Eur J Cancer. 2012 May;48(7):961–973.
37. Ou SH, Bartlett CH, Mino-Kenudson M, et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer:a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist. 2012;17(11):1351–1375.
38. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 Sep 10;27(26):4247–4253.
39. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 Jun 20;368(25):2385–2394.
40. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014 Dec 4;371(23):2167–2177.
41. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009 Apr 15;115(8):1723–1733.
42. Kerr KM. ALK testing in non-small cell lung carcinoma:what now? J Thorac Oncol. 2014 May;9(5):593–595.
43. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28;363(18):1693–1703.
44. Tsao M, Hirsch F, Yatabe Y. IASLC atlas of ALK testing in lung cancer. International association for the study of lung cancer. Aurora (CO):IASLC Press Office; 2013.
45. Bavieri M, Tiseo M, Lantuejoul S, et al. Fishing for ALK with immunohistochemistry may predict response to crizotinib. Tumori. 2013 Sep-Oct;99(5):e229–e232.
46. Rossi G, Ragazzi M, Tamagnini I, et al. Does immunohistochemistry represent a robust alternative technique in determining drugable predictive gene alterations in non-small cell lung cancer? Curr Drug Targets. 2015 Apr 22. [Epub ahead of print]
47. Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015 Mar;20(3):316–322.
48. Cabillic F, Gros A, Dugay F, et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol. 2014 Mar;9(3):295–306.
49. Ilie MI, Bence C, Hofman V, et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number:a potential major issue for anti-ALK therapeutic strategies. Ann Oncol. 2015 Jan;26(1):238–244.
50. Marchetti A, Di Lorito A, Pace MV, et al. ALK protein analysis by IHC staining after recent regulatory changes:A comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol. 2016 Apr;11(4):487–495.
51. Ren S, Hirsch FR, Varella-Garcia M, et al. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol. 2014 Mar;9(3):e21–e23.
52. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma:a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013 Dec;26(12):1545–1553.
53. Wynes MW, Sholl LM, Dietel M, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol. 2014 May;9(5):631–638.
54. Wang R, Pan Y, Li C, et al. The use of quantitative real-time reverse transcriptase PCR for 5ʹ and 3ʹ portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res. 2012 Sep 1;18(17):4725–4732.
55. Liu L, Zhan P, Zhou X, et al. Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods. Plos One. 2015;10(3):e0117032.
56. Soda M, Isobe K, Inoue A, et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res. 2012 Oct 15;18(20):5682–5689.
57. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007 May 1;67(9):4408–4417.
58. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20;371(21):1963–1971.• The first evidence of the activity of crizotinib in patients with NSCLC and ROS1 rearrangement.
59. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer:updated results from a phase 1 study. Lancet Oncol. 2012 Oct;13(10):1011–1019.
60. Crino L, Kim D, Riely GJ, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC):PROFILE 1005. ASCO Meet Abstr. 2011 June 9;29(15_suppl):7514.
61. Kim D-W, Ahn M-J, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2012 May 30;30(15_suppl):7533.
62. Blackhall FH, Evans TL, Han J, et al. Impact of crizotinib treatment on patient-reported symptoms and quality of life (QoL) in advanced ALK-positive non-small cell lung cancer (NSCLC) [1231PD]. Ann Oncol. 2012;23(Suppl 9):ixe 403. Proceedings of the 37th European Society for Medical Oncology meeting; 2012.
63. Shaw AT, Janne PA, Besse B, et al. Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC):final survival results from PROFILE 1007. ASCO Meet Abstr. 2016 May 31;34(15_suppl):9066.
64. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 1;22(9):1589–1597.
65. Lu S, Mok T, Lu Y, et al. Phase 3 study of first-line crizotinib vs pemetrexed-cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2016 May 31;34(15_suppl):9058.
66. Ou SH, Janne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol. 2014 Feb;25(2):415–422.
67. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012 Dec;7(12):1807–1814.
68. Weickhardt AJ, Doebele RC, Purcell WT, et al. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 2013 Jul 1;119(13):2383–2390.
69. Heuckmann JM, Balke-Want H, Malchers F, et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res. 2012 Sep 1;18(17):4682–4690.
70. Horn L, Pao W. EML4-ALK:honing in on a new target in non-small-cell lung cancer. J Clin Oncol. 2009 Sep 10;27(26):4232–4235.
71. Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010 Jul;46(10):1773–1780.
72. Workman P, van Montfort R. EML4-ALK fusions:propelling cancer but creating exploitable chaperone dependence. Cancer Discov. 2014 Jun;4(6):642–645.
73. Camidge DR, Doebele RC. ALKTreating -positive lung cancer–early successes and future challenges. Nat Rev Clin Oncol. 2012 May;9(5):268–277.
74. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010 Oct 28;363(18):1734–1739.
75. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012 Mar 1;18(5):1472–1482.
76. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014 Jun;4(6):662–673.
77. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012 Feb 8;4(120):120ra17.
78. Shaw AT, Camidge DR, Felip E, et al. Results of a first-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. ESMO Annual Meeting; 2012 Sep 28–Oct 02; Vienna.• The first evidence of efficacy in humans of a new inhibitor of ALK different from crizotinib.
79. Li N, Michellys P-Y, Kim S, et al. Abstract B232:activity of a potent and selective phase I ALK inhibitor LDK378 in naive and crizotinib-resistant preclinical tumor models. Am Assoc Cancer Res. 2011 Nov 12;10(11 Supplement):B232–B232.
80. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Mar 27;370(13):1189–1197.
81. Felip E, Kim D, Mehra R, et al. 1295Pefficacy and safety of ceritinib in patients (PTS) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC):an update of ascend-1. Ann Oncol. 2014 September 1;25(suppl 4):iv456–iv457.
82. Kim DW, Mehra R, Tan DS, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1):updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016 Apr;17(4):452–463.
83. Tan DS-W, Kim D-W, Thomas M, et al. Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1. ASCO Meet Abstr. 2016 May 31;34(15_suppl):9064.
84. Mok T, Spigel D, Felip E, et al. ASCEND-2:A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). ASCO Meet Abstr. 2015 May 18;33(15_suppl):8059.
85. Gainor JF, Tan DS, De Pas T, et al. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential Crizotinib and Ceritinib. Clin Cancer Res. 2015 Jun 15;21(12):2745–2752.
86. Felip E, Orlov S, Park K, et al. ASCEND-3:A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naive adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2015 May 18;33(15_suppl):8060.
87. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679–690.
88. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study):a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013 Jun;14(7):590–598.
89. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG):results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014 Sep;15(10):1119–1128.
90. Ou SH, Ahn JS, De Petris L, et al. Alectinib in Crizotinib-refractory ALK-rearranged non-small-cell lung cancer:A phase II global study. J Clin Oncol. 2016 Mar 1;34(7):661–668.
91. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer:a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016 Feb;17(2):234–242.
92. Yang JC-H, Ou S-HI, De Petris L, et al. Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC):pooled data from two pivotal phase II studies (NP28673 and NP28761). ASCO Meet Abstr. 2016 May 31;34(15_suppl):e20507.
93. Puig O, Yang JC-H, Ou S-HI, et al. Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC). ASCO Meet Abstr. 2016 May 31;34(15_suppl):9061.
94. Nokihara H, Hida T, Kondo M, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC):Primary results from the J-ALEX study. ASCO Meet Abstr. 2016 May 31;34(15_suppl):9008.
95. Zhang S, Nadworny S, Wardwell SD, et al. Abstract 781:The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models. Cancer Res. 2015 Aug 01;75(15 Supplement):781–781.
96. Ceccon M, Mologni L, Giudici G, et al. Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma. Mol Cancer Res. 2015 Apr;13(4):775–783.
97. Rosell R, Gettinger SN, Bazhenova LA, et al. 1330:Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial. J Thorac Oncol. 2016;11(4):S114.
98. Kim D-W, Tiseo M, Ahn M-J, et al. Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC):first report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA). ASCO Meet Abstr. 2016 May 31;34(15_suppl):9007.
99. Gettinger SN, Zhang S, Hodgson JG, et al. Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status. ASCO Meet Abstr. 2016 May 31;34(15_suppl):9060.
100. Ou SH, Klempner SJ, Greenbowe JR, et al. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol. 2014 Dec;9(12):1821–1825.
101. Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014 Jun 12;57(11):4720–4744.
102. Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015 Jul 13;28(1):70–81.
103. Bauer T, Solomon B, Besse B. Clinical activity and safety of the ALK/ROS1 TKI inhibitor PF-06463922 in advanced NSCLC. J Thor Oncol. 2015;10:S239.
104. Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to Crizotinib by the Lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016 Jan 7;374(1):54–61.
105. Ardini E, Menichincheri M, De Ponti C, et al. Abstract A243:characterization of NMS‐E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK‐dependent lymphoma and non‐small cell lung cancer models. Am Assoc Cancer Res. 2009 Dec 10;8(12 Supplement):A244–A244.
106. Ardini E, Menichincheri M, Banfi P, et al. Abstract A232:In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori. Am Assoc Cancer Res. 2011 Nov 12;10(11 Supplement):A232–A232.
107. Farago AF, Le LP, Zheng Z, et al. Durable clinical response to Entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol. 2015 Dec;10(12):1670–1674.
108. Drilon A, Braud FD, Siena S, Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements. AACR Annual Meeting; 2016 April 16–20; New Orleans, LA.
109. Horn L, Wakelee HA, Reckamp KL, et al. Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2016 May 31;34(15_suppl):9056.
110. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011 May 20;29(15):e443–e445.
111. Metro G, Lunardi G, Floridi P, et al. CSF concentration of Crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol. 2015 May;10(5):e26–e27.
112. Costa DB, Shaw AT, Ou SH, et al. Clinical experience with Crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015 Jun 10;33(17):1881–1888.
113. Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial efficacy of Crizotinib versus Chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer:results from PROFILE 1014. J Clin Oncol. 2016 Aug 20;34(24):2858–2865.
114. Johung KL, Yeh N, Desai NB, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol. 2016 Jan 10;34(2):123–129.
115. Gadgeel SM, Shaw AT, Barlesi F, et al. Cumulative incidence rates for CNS and non-CNS progression by baseline CNS metastases status using data from two alectinib phase II studies. ASCO Meet Abstr. 2016 May 31;34(15_suppl):9063.
116. Gadgeel S, Shaw A, Ramaswamy G. Pooled analysis of CNS response to alectinib in two studies of pre-treated ALK+ NSCLC. J Thorac Oncol. 2015;10:S238.
117. Chen Z, Sasaki T, Tan X, et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 2010 Dec 1;70(23):9827–9836.
118. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535–7540.
119. Socinski MA, Goldman J, El-Hariry I, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 1;19(11):3068–3077.
120. Lee J-S, Han J-Y, Ahn M-J, et al. Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC:results of a randomized phase 2 study. ASCO Meet Abstr. 2016 May 31;34(15_suppl):9059.
121. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010 Nov 20;28(33):4953–4960.
122. Felip E, Carcereny E, Barlesi F. Phase II activity of the Hsp90 inhibitor AUY922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2012;23(Suppl 9):ix152–ix174, 438.
123. Camidge DR, Kono SA, Lu X, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 2011 Apr;6(4):774–780.
124. Lee JO, Kim TM, Lee SH, et al. Anaplastic lymphoma kinase translocation:a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol. 2011 Sep;6(9):1474–1480.
125. Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer. 2011 May 10;104(10):1594–1601.
126. McCoach CE, Le AT, Aisner D, et al. Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer. ASCO Meet Abstr. 2016 May 31;34(15_suppl):9065.
127. Isozaki H, Ichihara E, Takigawa N, et al. Non-small cell lung cancer cells acquire resistance to the ALK inhibitor Alectinib by activating alternative receptor tyrosine kinases. Cancer Res. 2016 Mar 15;76(6):1506–1516.
128. Hrustanovic G, Olivas V, Pazarentzos E, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep;21(9):1038–1047.
129. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627–1639.
130. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540–1550.
131. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational Landscape Determines Sensitivity to PD-1 Blockade in Non-Small Cell Lung Cancer. Science. 2015 Apr 3;348(6230):124–128.
132. Martinengo C, Poggio T, Menotti M, et al. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis. Cancer Res. 2014 Nov 1;74(21):6094–6106.